PFIZER - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | PFIZER | Market Cap | 20,732 Cr. | Current Price | 4,539 ₹ | High / Low | 5,896 ₹ |
| Stock P/E | 27.3 | Book Value | 919 ₹ | Dividend Yield | 1.65 % | ROCE | 24.2 % |
| ROE | 18.0 % | Face Value | 10.0 ₹ | DMA 50 | 4,657 ₹ | DMA 200 | 4,846 ₹ |
| Chg in FII Hold | 0.10 % | Chg in DII Hold | -0.16 % | PAT Qtr | 193 Cr. | PAT Prev Qtr | 182 Cr. |
| RSI | 45.7 | MACD | -53.6 | Volume | 22,161 | Avg Vol 1Wk | 18,545 |
| Low price | 4,397 ₹ | High price | 5,896 ₹ | PEG Ratio | 3.39 | Debt to equity | 0.02 |
| 52w Index | 9.52 % | Qtr Profit Var | -2.64 % | EPS | 158 ₹ | Industry PE | 32.1 |
📊 Entry Price Zone: 4,450 ₹ – 4,650 ₹ (ideal accumulation range near DMA support levels)
📈 Exit / Holding Strategy: If already holding, maintain a 3–5 year horizon given strong ROE/ROCE and low debt. Exit only if price sustains below 4,450 ₹ or if profitability metrics weaken further.
Positive
✅ Strong ROCE (24.2%) and ROE (18.0%) indicate efficient capital use.
✅ EPS of 158 ₹ supports valuation strength.
✅ Dividend yield at 1.65% provides steady income support.
✅ Debt-to-equity ratio at 0.02 shows excellent financial stability.
✅ PAT growth from 182 Cr. to 193 Cr. reflects resilience.
✅ FII holdings increased (+0.10%), showing foreign investor confidence.
✅ RSI (45.7) suggests near oversold territory, offering rebound potential.
Limitation
⚠️ PEG ratio (3.39) highlights expensive growth relative to earnings.
⚠️ Current P/E (27.3) is slightly below industry average (32.1), but valuations remain stretched.
⚠️ MACD (-53.6) signals weak short-term momentum.
⚠️ DII holding decreased (-0.16%), reflecting weaker domestic institutional support.
⚠️ Price remains far below 52-week high of 5,896 ₹, showing capped upside.
Company Negative News
❌ Quarterly profit variation (-2.64%) highlights mild earnings pressure.
❌ Domestic institutional outflows (-0.16%) weaken sentiment.
❌ Technicals show price below DMA 50 (4,657 ₹) and DMA 200 (4,846 ₹).
Company Positive News
🌟 PAT remained stable despite slight decline, reflecting operational resilience.
🌟 Strong fundamentals with consistent dividend payout.
🌟 FII inflows (+0.10%) support investor confidence.
Industry
💊 Pharmaceutical sector supported by rising demand for healthcare and generics.
📊 Industry PE at 32.1 suggests peers trade at higher valuations.
📈 Long-term demand outlook favorable due to global healthcare expansion.
Conclusion
🔎 PFIZER demonstrates strong fundamentals with high ROE/ROCE, low debt, and stable profitability. Despite stretched valuations and mild earnings pressure, it remains a moderately strong candidate for long-term investment. Accumulation is best in the 4,450 ₹ – 4,650 ₹ zone. For existing holders, a 3–5 year horizon is favorable, with exit only if price breaks below 4,450 ₹ or fundamentals deteriorate.
Would you like me to expand this into a peer benchmarking against Sun Pharma, Dr. Reddy’s, and Cipla, or refine it into a swing trading setup with short-term entry/exit levels?